|
|
| | (R)-BAY1238097 Basic information |
| Product Name: | (R)-BAY1238097 | | Synonyms: | (R)-BAY1238097;3H-2,3-Benzodiazepine-3-carboxamide, 4,5-dihydro-7,8-dimethoxy-N,4-dimethyl-1-[4-(4-methyl-1-piperazinyl)phenyl]-, (4R)-;(R)BAY1238097,(R) BAY1238097,(R)-BAY-1238097 | | CAS: | 1564269-85-7 | | MF: | C25H33N5O3 | | MW: | 451.56 | | EINECS: | | | Product Categories: | | | Mol File: | 1564269-85-7.mol |  |
| | (R)-BAY1238097 Chemical Properties |
| density | 1.22±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 150 mg/mL (332.18 mM);Water : < 0.1 mg/mL (insoluble) | | form | Solid | | pka | 15.43±0.60(Predicted) | | color | Light yellow to yellow |
| | (R)-BAY1238097 Usage And Synthesis |
| Description | (R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome[1][2].
BET[1]. | | References | [1]. Lejeune, P., et al. (2015) Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models. Cancer Research, 75(15 Suppl), 884.
[2]. Bernasconi E, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948. |
| | (R)-BAY1238097 Preparation Products And Raw materials |
|